JP2019500320A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500320A5
JP2019500320A5 JP2018522569A JP2018522569A JP2019500320A5 JP 2019500320 A5 JP2019500320 A5 JP 2019500320A5 JP 2018522569 A JP2018522569 A JP 2018522569A JP 2018522569 A JP2018522569 A JP 2018522569A JP 2019500320 A5 JP2019500320 A5 JP 2019500320A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
rsv
protein
virus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522569A
Other languages
English (en)
Japanese (ja)
Other versions
JP7311872B2 (ja
JP2019500320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/058976 external-priority patent/WO2017075125A1/en
Publication of JP2019500320A publication Critical patent/JP2019500320A/ja
Publication of JP2019500320A5 publication Critical patent/JP2019500320A5/ja
Priority to JP2023065428A priority Critical patent/JP2023100654A/ja
Application granted granted Critical
Publication of JP7311872B2 publication Critical patent/JP7311872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522569A 2015-10-29 2016-10-27 キメラｒｓｖ、免疫原性組成物、及び使用方法 Active JP7311872B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065428A JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US62/247,962 2015-10-29
US201662334547P 2016-05-11 2016-05-11
US62/334,547 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065428A Division JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Publications (3)

Publication Number Publication Date
JP2019500320A JP2019500320A (ja) 2019-01-10
JP2019500320A5 true JP2019500320A5 (https=) 2019-12-05
JP7311872B2 JP7311872B2 (ja) 2023-07-20

Family

ID=58630734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018522569A Active JP7311872B2 (ja) 2015-10-29 2016-10-27 キメラｒｓｖ、免疫原性組成物、及び使用方法
JP2023065428A Pending JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065428A Pending JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Country Status (10)

Country Link
US (2) US11235050B2 (https=)
EP (1) EP3368547A4 (https=)
JP (2) JP7311872B2 (https=)
KR (1) KR20180085730A (https=)
CN (1) CN108602858A (https=)
BR (1) BR112018008708A2 (https=)
CA (1) CA3003726A1 (https=)
MX (1) MX2018005462A (https=)
SG (1) SG11201803581VA (https=)
WO (1) WO2017075125A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3798310A1 (en) 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
MX2021005607A (es) * 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
EP3923983A4 (en) 2019-02-11 2023-02-22 Emory University CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
EP4319880A4 (en) * 2021-04-08 2025-03-19 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US20020018780A1 (en) * 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
EP1613345B1 (en) 2003-03-28 2010-05-26 MedImmune, LLC Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
PT1699919T (pt) 2003-12-24 2017-04-03 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Volksgezondheid Welzijn En Sport Um vírus sincicial respiratório com deficiência genómica complementada em trans
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
KR101621100B1 (ko) 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
US9011876B2 (en) 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US20110097358A1 (en) 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
CA2835644C (en) * 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
EP4190895A1 (en) 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP3798310A1 (en) 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions

Similar Documents

Publication Publication Date Title
JP2019500320A5 (https=)
US11389523B2 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
Lee et al. Mechanisms of cross-protection by influenza virus M2-based vaccines
JP6990814B2 (ja) アヒル腸炎ウイルス及びその使用
JP7046014B2 (ja) 伝染性喉頭気管炎ウイルスおよび伝染性ファブリキウス嚢病ウイルスの抗原をコードする組換え非病原性マレック病ウイルスコンストラクト
JP2017503482A5 (https=)
JP2017522907A5 (https=)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
US7244435B2 (en) DNA vaccine expressing HA1 of equine-2 influenza virus
JP6802813B2 (ja) アヒル腸炎ウイルス及びその使用
CN104353070B (zh) 一种鸡传染性支气管炎病毒的基因工程亚单位疫苗及其制备方法
CN104293741A (zh) 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
WO2020215350A1 (zh) 禽流感与禽腺病毒4型二联基因工程亚单位疫苗及其制备方法
CN104031889A (zh) 表达传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒疫苗及应用
Ying et al. Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle
WO2005054451A1 (ja) 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
CN107344969B (zh) 一种纳米流感疫苗及构建方法和应用
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
CN113430178B (zh) 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
Allam et al. Perspective vaccines for emerging viral diseases in farm animals
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
CN103316357B (zh) 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法
Mu et al. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン